Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.
Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-negative breast cancer (Abstract 1008).
Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).
Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).
Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
